
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a global life sciences manufacturer with two segments, protein sciences (75% of revenue) and diagnostics and genomics (25% of revenue). The company has a global presence with operations in the US (55% of revenue), Europe, the Middle East, Africa, the UK, and Asia-Pacific. The pending acquisition of Wilson Wolf is seen as a transformative move with potential for improved margins and growth opportunities. Regulatory risk is low and an important driver of future growth is the expected rebound in biotech demand.
Bears say
Bio-Techne is a global life science tools company that has seen a mixed track record in M&A activity, but has made successful acquisitions in the past. However, concerns about potential share loss to larger competitors and fast-growing start-ups, as well as the progress of cell therapy development, could lead to downside risks for the company's stock. There is also a possibility of structural growth pressures if wet lab work is diminished by dry lab work in the future. The current 20x EBITDA multiple for Bio-Techne is a premium to the peer group median of 16x, but reflects the company's ongoing business recovery and improving growth momentum.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares